Authors: Paul Lee¹, Gülce Naz Ünsal², Selin Demirel², Tanvi Verma¹, Feza Korkusuz² — ¹ MSK Doctors & Associates Ltd., UK · ² Hacettepe University, Türkiye

Orthobiologic therapies such as hyaluronic acid (HA), platelet-rich plasma (PRP), growth factor peptides, and stromal (stem) cell injections are increasingly used to modulate pain, inflammation and tissue homeostasis in degenerative joint conditions such as knee osteoarthritis (KOA). These interventions aim not only for symptomatic relief, but ideally to alter disease trajectory by promoting joint preservation and regeneration. However, in many clinical settings, the evaluation of success is limited to patient-reported outcomes (pain, function scores) and occasional imaging (e.g. MRI). Such assessments may miss early or subtle functional improvements in movement quality or neuromuscular control that precede macroscopic changes.

In the presentation \"Does Marker-less Motion Analysis Technology Predict Movement Quality after Intra-articular Orthobiologic Injections?\", delivered at the 2nd European Symposium on interprofessional Collaboration on Osteoarthritis management conference in Porto, Portugal, 2025, we explored whether MAI Motion, a marker-less motion capture platform can detect functional changes in patients with KOA receiving intra-articular orthobiologic injections. The core hypothesis is that improvements in movement quality (e.g. smoother transitions, more symmetric loading) may manifest before structural changes become appreciable, and these can be objectively quantified through MAI Motion.

Using MAI Motion, we captured kinematic profiles of patients both before and after treatment (at serial time-points). Importantly, we investigated whether baseline movement features could identify improvement in patients after orthobiologic injections.